Skip to main content

Table 5 Poisson multivariate regression model for number of flares during follow-up of 12 months by sex

From: Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

  

Females (N = 43,304)

Males (N = 134,333)

  

IRR

95% CI

p-value

IRR

95% CI

p-value

Age

< 50

1.00

(ref.)

 

1.00

(ref.)

 
 

50 - 59

1.66

(1.49, 1.85)

< .0001

0.83

(0.80, 0.85)

< .0001

 

60 - 69

1.93

(1.73, 2.16)

< .0001

0.76

(0.73, 0.79)

< .0001

 

70 - 79

1.69

(1.51, 1.90)

< .0001

0.56

(0.53, 0.60)

< .0001

 

80 - 89

1.31

(1.12, 1.52)

0.001

0.53

(0.48, 0.59)

< .0001

Comorbidities:

       

Cardiometabolic*

 

1.60

(1.48, 1.74)

< .0001

1.10

(1.06, 1.13)

< .0001

Diabetes

 

1.48

(1.35, 1.63)

< .0001

0.97

(0.93, 1.02)

0.262

Gastrointestinal

 

0.86

(0.78, 0.96)

0.005

1.07

(1.02, 1.13)

0.011

Hematological

 

1.03

(0.88, 1.20)

0.720

0.94

(0.84, 1.06)

0.340

Myopathy

 

1.21

(0.50, 2.91)

0.670

0.84

(0.50, 1.42)

0.509

Osteoporosis

 

0.88

(0.78, 1.00)

0.044

1.11

(0.99, 1.25)

0.076

  1. IRR = Incidence rate ratio.
  2. * Cardiometabolic disease include congestive heart failure, ischaemic heart disease, hypertension, cerebrovascular disease, peripheral arterial disease, dyslipidemia.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us